Physician profile
Eric Geiser
NPI 1316007503
$11,242.30
in general payments reported to CMS, 2019-2025
15 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $17.76 · 2021: $22.98 · 2022: $174 · 2023: $10K · 2024: $91.76 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,117 · Travel and Lodging: $1,002 · Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,117.37 |
| Travel and Lodging | $1,001.93 |
| Food and Beverage | $783.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,247.32 | 2023-2025 | Da Vinci Surgical System, Ion |
| Astrazeneca Pharmaceuticals Lp | $300.33 | 2020-2025 | Airsupra, Breztri, Tezspire |
| United Therapeutics Corporation | $159.21 | 2025 | Tyvaso |
| Pulmonx Corporation | $125.61 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.52 | 2021-2023 | Ofev |
| Insmed, INC. | $49.00 | 2024-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $46.07 | 2025 | Glassia |
| Grifols USA, LLC | $32.82 | 2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $28.33 | 2023 | Nucala |
| Actelion Pharmaceuticals US, INC. | $25.62 | 2022 | |
| Genzyme Corporation | $21.55 | 2023 | |
| Amgen INC. | $16.95 | 2024 | Tezspire |
| Genentech USA, INC. | $16.10 | 2025 | Xolair |
| Inogen, INC. | $15.88 | 2023 | Inogen One G3 Oxygen Concentrator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Geiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.